KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other financing activities (2018 - 2024)

Historic Other financing activities for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q3 2024 value amounting to -$1.8 million.

  • Alnylam Pharmaceuticals' Other financing activities fell 12124.08% to -$1.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $8.3 million, marking a year-over-year decrease of 6503.17%. This contributed to the annual value of $24.7 million for FY2023, which is 2042.9% down from last year.
  • According to the latest figures from Q3 2024, Alnylam Pharmaceuticals' Other financing activities is -$1.8 million, which was down 12124.08% from -$1.3 million recorded in Q2 2024.
  • In the past 5 years, Alnylam Pharmaceuticals' Other financing activities ranged from a high of $8.3 million in Q4 2023 and a low of -$1.8 million during Q3 2024
  • For the 5-year period, Alnylam Pharmaceuticals' Other financing activities averaged around $4.9 million, with its median value being $4.2 million (2020).
  • In the last 5 years, Alnylam Pharmaceuticals' Other financing activities soared by 11428.57% in 2022 and then crashed by 13205.0% in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Other financing activities stood at $4.2 million in 2020, then fell by 16.67% to $3.5 million in 2021, then soared by 114.29% to $7.5 million in 2022, then rose by 11.12% to $8.3 million in 2023, then tumbled by 121.24% to -$1.8 million in 2024.
  • Its Other financing activities stands at -$1.8 million for Q3 2024, versus -$1.3 million for Q2 2024 and $3.1 million for Q1 2024.